Vyant Bio, Inc. Common Stock
VYNT
VYNT was delisted on the 12th of May, 2023.
32 hedge funds and large institutions have $10.5M invested in Vyant Bio, Inc. Common Stock in 2015 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 14 increasing their positions, 6 reducing their positions, and 6 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 6
11% less funds holding
Funds holding: 36 → 32 (-4)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
36% less capital invested
Capital invested by funds: $16.3M → $10.5M (-$5.81M)
43% less call options, than puts
Call options by funds: $8K | Put options by funds: $14K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIP
Granite Investment Partners
El Segundo,
California
|
+$491K |
| 2 |
MAG
Millrace Asset Group
Berwyn,
Pennsylvania
|
+$282K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$149K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
+$144K |
| 5 |
DIA
Denver Investment Advisors
Denver,
Colorado
|
+$144K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Royce & Associates
New York
|
-$403K |
| 2 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
-$256K |
| 3 |
Millennium Management
New York
|
-$153K |
| 4 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
-$131K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$92K |
VYNT Hedge Fund Activity: Q3 2015 in Review
32 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Vyant Bio, Inc. Common Stock (VYNT) for Q3 2015, worth a combined $10.5M — down 36% from $16.3M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of VYNT and 4 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 14 added.
The largest buyer was Granite Investment Partners, adding an estimated $491K. The largest seller was Royce & Associates, cutting an estimated $403K.
- 32 institutional investors held Vyant Bio, Inc. Common Stock (VYNT) as of Q3 2015, down from 36 in Q2 2015.
- Funds reported $10.5M of Vyant Bio, Inc. Common Stock stock for Q3 2015, down 36% quarter-over-quarter.
- 4 funds opened new Vyant Bio, Inc. Common Stock positions in Q3 2015 and 6 closed out, a net change of -2 holders.
- The largest Vyant Bio, Inc. Common Stock buyer in Q3 2015 was Granite Investment Partners, an estimated $491K added.
- The largest Vyant Bio, Inc. Common Stock seller in Q3 2015 was Royce & Associates, an estimated $403K sold.
Based on aggregated 13F filings for Q3 2015.